nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisuride—DRD4—conduct disorder	0.597	0.685	CbGaD
Lisuride—HTR2A—conduct disorder	0.275	0.316	CbGaD
Lisuride—Cabergoline—DRD4—conduct disorder	0.00208	0.268	CrCbGaD
Lisuride—Pergolide—DRD4—conduct disorder	0.0016	0.207	CrCbGaD
Lisuride—Cabergoline—HTR2A—conduct disorder	0.000957	0.123	CrCbGaD
Lisuride—Methylergometrine—HTR2A—conduct disorder	0.000957	0.123	CrCbGaD
Lisuride—Methysergide—HTR2A—conduct disorder	0.000799	0.103	CrCbGaD
Lisuride—Pergolide—HTR2A—conduct disorder	0.00074	0.0954	CrCbGaD
Lisuride—Ergotamine—HTR2A—conduct disorder	0.000617	0.0796	CrCbGaD
Lisuride—HTR2A—autonomic nervous system—conduct disorder	0.000454	0.215	CbGeAlD
Lisuride—DRD4—brain—conduct disorder	0.000224	0.106	CbGeAlD
Lisuride—DRD3—brain—conduct disorder	0.000157	0.0746	CbGeAlD
Lisuride—DRD5—brain—conduct disorder	0.000148	0.0699	CbGeAlD
Lisuride—ADRA1B—brain—conduct disorder	0.000121	0.0573	CbGeAlD
Lisuride—ADRA1D—brain—conduct disorder	0.000118	0.056	CbGeAlD
Lisuride—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000118	0.000996	CbGpPWpGaD
Lisuride—HTR2B—Signaling by GPCR—CGA—conduct disorder	0.000117	0.000992	CbGpPWpGaD
Lisuride—HTR1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000117	0.000987	CbGpPWpGaD
Lisuride—DRD4—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000115	0.000971	CbGpPWpGaD
Lisuride—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.000114	0.000967	CbGpPWpGaD
Lisuride—DRD1—brain—conduct disorder	0.000113	0.0534	CbGeAlD
Lisuride—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000111	0.000939	CbGpPWpGaD
Lisuride—DRD1—Signaling by GPCR—CGA—conduct disorder	0.000111	0.000935	CbGpPWpGaD
Lisuride—HTR2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00011	0.000927	CbGpPWpGaD
Lisuride—ADRB1—GPCR downstream signaling—CGA—conduct disorder	0.00011	0.000926	CbGpPWpGaD
Lisuride—ADRA1D—Signaling by GPCR—CGA—conduct disorder	0.000109	0.000923	CbGpPWpGaD
Lisuride—DRD3—Signaling by GPCR—CGA—conduct disorder	0.000109	0.000923	CbGpPWpGaD
Lisuride—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000109	0.000918	CbGpPWpGaD
Lisuride—ADRB1—GPCR ligand binding—DRD4—conduct disorder	0.000109	0.000918	CbGpPWpGaD
Lisuride—ADRA2B—GPCR downstream signaling—CGA—conduct disorder	0.000109	0.000917	CbGpPWpGaD
Lisuride—ADRA2B—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000108	0.000909	CbGpPWpGaD
Lisuride—ADRA2B—GPCR ligand binding—DRD4—conduct disorder	0.000108	0.000909	CbGpPWpGaD
Lisuride—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000107	0.000906	CbGpPWpGaD
Lisuride—HTR1A—GPCR downstream signaling—CGA—conduct disorder	0.000105	0.000886	CbGpPWpGaD
Lisuride—HTR2C—GPCR downstream signaling—CGA—conduct disorder	0.000104	0.000881	CbGpPWpGaD
Lisuride—HTR1A—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000104	0.000878	CbGpPWpGaD
Lisuride—HTR1A—GPCR ligand binding—DRD4—conduct disorder	0.000104	0.000878	CbGpPWpGaD
Lisuride—DRD1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000103	0.000874	CbGpPWpGaD
Lisuride—HTR2C—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000103	0.000873	CbGpPWpGaD
Lisuride—HTR2C—GPCR ligand binding—DRD4—conduct disorder	0.000103	0.000873	CbGpPWpGaD
Lisuride—DRD5—GPCR downstream signaling—DRD4—conduct disorder	0.000103	0.000868	CbGpPWpGaD
Lisuride—ADRA1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000102	0.000863	CbGpPWpGaD
Lisuride—DRD3—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000102	0.000863	CbGpPWpGaD
Lisuride—ADRA2C—GPCR downstream signaling—CGA—conduct disorder	0.000101	0.000857	CbGpPWpGaD
Lisuride—ADRA2C—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.0001	0.000849	CbGpPWpGaD
Lisuride—ADRA2C—GPCR ligand binding—DRD4—conduct disorder	0.0001	0.000849	CbGpPWpGaD
Lisuride—ADRA1B—GPCR downstream signaling—CGA—conduct disorder	9.98e-05	0.000843	CbGpPWpGaD
Lisuride—ADRB1—Signaling by GPCR—CGA—conduct disorder	9.95e-05	0.000841	CbGpPWpGaD
Lisuride—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	9.89e-05	0.000836	CbGpPWpGaD
Lisuride—ADRA1B—GPCR ligand binding—DRD4—conduct disorder	9.89e-05	0.000836	CbGpPWpGaD
Lisuride—ADRA2B—Signaling by GPCR—CGA—conduct disorder	9.86e-05	0.000833	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—CGA—conduct disorder	9.84e-05	0.000832	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—CGA—conduct disorder	9.52e-05	0.000804	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—CGA—conduct disorder	9.47e-05	0.0008	CbGpPWpGaD
Lisuride—DRD5—Signaling by GPCR—DRD4—conduct disorder	9.33e-05	0.000788	CbGpPWpGaD
Lisuride—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	9.3e-05	0.000786	CbGpPWpGaD
Lisuride—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	9.22e-05	0.000779	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—CGA—conduct disorder	9.21e-05	0.000778	CbGpPWpGaD
Lisuride—DRD2—GPCR downstream signaling—CGA—conduct disorder	9.2e-05	0.000778	CbGpPWpGaD
Lisuride—HTR1B—brain—conduct disorder	9.14e-05	0.0433	CbGeAlD
Lisuride—DRD2—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	9.12e-05	0.000771	CbGpPWpGaD
Lisuride—DRD2—GPCR ligand binding—DRD4—conduct disorder	9.12e-05	0.000771	CbGpPWpGaD
Lisuride—CYP2D6—Biological oxidations—COMT—conduct disorder	9.09e-05	0.000768	CbGpPWpGaD
Lisuride—HTR1D—GPCR ligand binding—HTR2A—conduct disorder	9.08e-05	0.000768	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—CGA—conduct disorder	9.06e-05	0.000766	CbGpPWpGaD
Lisuride—HTR2A—GPCR downstream signaling—CGA—conduct disorder	9.05e-05	0.000765	CbGpPWpGaD
Lisuride—CYP2D6—Biological oxidations—MAOA—conduct disorder	9.03e-05	0.000763	CbGpPWpGaD
Lisuride—HTR2A—GPCR ligand binding—DRD4—conduct disorder	8.97e-05	0.000758	CbGpPWpGaD
Lisuride—CYP2D6—Metapathway biotransformation—COMT—conduct disorder	8.96e-05	0.000758	CbGpPWpGaD
Lisuride—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	8.9e-05	0.000752	CbGpPWpGaD
Lisuride—HTR1B—GPCR ligand binding—HTR2A—conduct disorder	8.9e-05	0.000752	CbGpPWpGaD
Lisuride—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	8.85e-05	0.000748	CbGpPWpGaD
Lisuride—HTR1D—brain—conduct disorder	8.85e-05	0.0419	CbGeAlD
Lisuride—HTR2C—brain—conduct disorder	8.76e-05	0.0415	CbGeAlD
Lisuride—DRD4—GPCR ligand binding—HTR2A—conduct disorder	8.75e-05	0.00074	CbGpPWpGaD
Lisuride—DRD4—Circadian rythm related genes—EP300—conduct disorder	8.68e-05	0.000733	CbGpPWpGaD
Lisuride—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	8.61e-05	0.000728	CbGpPWpGaD
Lisuride—ADRB1—brain—conduct disorder	8.6e-05	0.0407	CbGeAlD
Lisuride—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	8.47e-05	0.000716	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—CGA—conduct disorder	8.36e-05	0.000706	CbGpPWpGaD
Lisuride—HTR2B—GPCR ligand binding—HTR2A—conduct disorder	8.36e-05	0.000706	CbGpPWpGaD
Lisuride—ADRA2A—GPCR downstream signaling—CGA—conduct disorder	8.24e-05	0.000696	CbGpPWpGaD
Lisuride—HTR1A—SIDS Susceptibility Pathways—EP300—conduct disorder	8.23e-05	0.000695	CbGpPWpGaD
Lisuride—HTR2B—brain—conduct disorder	8.23e-05	0.039	CbGeAlD
Lisuride—HTR2A—Signaling by GPCR—CGA—conduct disorder	8.22e-05	0.000695	CbGpPWpGaD
Lisuride—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	8.16e-05	0.00069	CbGpPWpGaD
Lisuride—ADRA2A—GPCR ligand binding—DRD4—conduct disorder	8.16e-05	0.00069	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—WASF1—conduct disorder	7.89e-05	0.000666	CbGpPWpGaD
Lisuride—DRD1—GPCR ligand binding—HTR2A—conduct disorder	7.88e-05	0.000666	CbGpPWpGaD
Lisuride—HTR1D—GPCR downstream signaling—DRD4—conduct disorder	7.87e-05	0.000665	CbGpPWpGaD
Lisuride—DRD1—Circadian rythm related genes—EP300—conduct disorder	7.81e-05	0.00066	CbGpPWpGaD
Lisuride—DRD2—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	7.81e-05	0.00066	CbGpPWpGaD
Lisuride—ADRA1D—GPCR ligand binding—HTR2A—conduct disorder	7.77e-05	0.000657	CbGpPWpGaD
Lisuride—DRD3—GPCR ligand binding—HTR2A—conduct disorder	7.77e-05	0.000657	CbGpPWpGaD
Lisuride—DRD3—Circadian rythm related genes—EP300—conduct disorder	7.71e-05	0.000651	CbGpPWpGaD
Lisuride—HTR1B—GPCR downstream signaling—DRD4—conduct disorder	7.7e-05	0.000651	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—CGA—conduct disorder	7.54e-05	0.000637	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—CGA—conduct disorder	7.48e-05	0.000632	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—CGA—conduct disorder	7.38e-05	0.000624	CbGpPWpGaD
Lisuride—HTR1A—brain—conduct disorder	7.37e-05	0.0349	CbGeAlD
Lisuride—DRD4—Signaling Pathways—CGA—conduct disorder	7.26e-05	0.000614	CbGpPWpGaD
Lisuride—HTR2B—GPCR downstream signaling—DRD4—conduct disorder	7.24e-05	0.000612	CbGpPWpGaD
Lisuride—HTR1D—Signaling by GPCR—DRD4—conduct disorder	7.15e-05	0.000604	CbGpPWpGaD
Lisuride—HTR2A—SIDS Susceptibility Pathways—EP300—conduct disorder	7.11e-05	0.000601	CbGpPWpGaD
Lisuride—ADRB1—GPCR ligand binding—HTR2A—conduct disorder	7.08e-05	0.000599	CbGpPWpGaD
Lisuride—ADRA2B—GPCR ligand binding—HTR2A—conduct disorder	7.02e-05	0.000593	CbGpPWpGaD
Lisuride—HTR1B—Signaling by GPCR—DRD4—conduct disorder	7e-05	0.000591	CbGpPWpGaD
Lisuride—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	6.99e-05	0.000591	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—CGA—conduct disorder	6.93e-05	0.000586	CbGpPWpGaD
Lisuride—DRD1—GPCR downstream signaling—DRD4—conduct disorder	6.83e-05	0.000577	CbGpPWpGaD
Lisuride—HTR1A—GPCR ligand binding—HTR2A—conduct disorder	6.78e-05	0.000573	CbGpPWpGaD
Lisuride—HTR2C—GPCR ligand binding—HTR2A—conduct disorder	6.74e-05	0.00057	CbGpPWpGaD
Lisuride—DRD3—GPCR downstream signaling—DRD4—conduct disorder	6.73e-05	0.000569	CbGpPWpGaD
Lisuride—ADRA1D—GPCR downstream signaling—DRD4—conduct disorder	6.73e-05	0.000569	CbGpPWpGaD
Lisuride—DRD5—GPCR downstream signaling—HTR2A—conduct disorder	6.7e-05	0.000566	CbGpPWpGaD
Lisuride—DRD2—brain—conduct disorder	6.66e-05	0.0315	CbGeAlD
Lisuride—HTR2B—Signaling by GPCR—DRD4—conduct disorder	6.57e-05	0.000555	CbGpPWpGaD
Lisuride—ADRA2C—GPCR ligand binding—HTR2A—conduct disorder	6.56e-05	0.000554	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—CGA—conduct disorder	6.54e-05	0.000552	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—CGA—conduct disorder	6.51e-05	0.00055	CbGpPWpGaD
Lisuride—ADRA2C—brain—conduct disorder	6.48e-05	0.0307	CbGeAlD
Lisuride—ADRA1B—GPCR ligand binding—HTR2A—conduct disorder	6.45e-05	0.000545	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—CGA—conduct disorder	6.45e-05	0.000545	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—CGA—conduct disorder	6.45e-05	0.000545	CbGpPWpGaD
Lisuride—DRD1—Signaling by GPCR—DRD4—conduct disorder	6.2e-05	0.000524	CbGpPWpGaD
Lisuride—ADRB1—GPCR downstream signaling—DRD4—conduct disorder	6.14e-05	0.000519	CbGpPWpGaD
Lisuride—ADRA1D—Signaling by GPCR—DRD4—conduct disorder	6.12e-05	0.000517	CbGpPWpGaD
Lisuride—DRD3—Signaling by GPCR—DRD4—conduct disorder	6.12e-05	0.000517	CbGpPWpGaD
Lisuride—DRD5—Signaling by GPCR—HTR2A—conduct disorder	6.09e-05	0.000514	CbGpPWpGaD
Lisuride—ADRA2B—GPCR downstream signaling—DRD4—conduct disorder	6.08e-05	0.000514	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—WASF1—conduct disorder	6.04e-05	0.00051	CbGpPWpGaD
Lisuride—DRD2—GPCR ligand binding—HTR2A—conduct disorder	5.95e-05	0.000503	CbGpPWpGaD
Lisuride—CYP3A4—Biological oxidations—COMT—conduct disorder	5.94e-05	0.000502	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—WASF1—conduct disorder	5.91e-05	0.0005	CbGpPWpGaD
Lisuride—CYP3A4—Biological oxidations—MAOA—conduct disorder	5.9e-05	0.000499	CbGpPWpGaD
Lisuride—DRD2—Circadian rythm related genes—EP300—conduct disorder	5.9e-05	0.000499	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—CGA—conduct disorder	5.88e-05	0.000497	CbGpPWpGaD
Lisuride—HTR1A—GPCR downstream signaling—DRD4—conduct disorder	5.87e-05	0.000496	CbGpPWpGaD
Lisuride—CYP3A4—Metapathway biotransformation—COMT—conduct disorder	5.86e-05	0.000495	CbGpPWpGaD
Lisuride—HTR2C—GPCR downstream signaling—DRD4—conduct disorder	5.84e-05	0.000493	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—CGA—conduct disorder	5.82e-05	0.000492	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—WASF1—conduct disorder	5.82e-05	0.000492	CbGpPWpGaD
Lisuride—ADRA2C—GPCR downstream signaling—DRD4—conduct disorder	5.68e-05	0.00048	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—CGA—conduct disorder	5.62e-05	0.000475	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—CGA—conduct disorder	5.59e-05	0.000473	CbGpPWpGaD
Lisuride—ADRA1B—GPCR downstream signaling—DRD4—conduct disorder	5.59e-05	0.000472	CbGpPWpGaD
Lisuride—ADRB1—Signaling by GPCR—DRD4—conduct disorder	5.57e-05	0.000471	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—WASF1—conduct disorder	5.56e-05	0.00047	CbGpPWpGaD
Lisuride—ADRA2B—Signaling by GPCR—DRD4—conduct disorder	5.52e-05	0.000467	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—DRD4—conduct disorder	5.51e-05	0.000466	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—CGA—conduct disorder	5.44e-05	0.00046	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—CGA—conduct disorder	5.35e-05	0.000452	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—DRD4—conduct disorder	5.33e-05	0.00045	CbGpPWpGaD
Lisuride—ADRA2A—GPCR ligand binding—HTR2A—conduct disorder	5.33e-05	0.00045	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—DRD4—conduct disorder	5.3e-05	0.000448	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—CGA—conduct disorder	5.28e-05	0.000447	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—WASF1—conduct disorder	5.24e-05	0.000443	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—WASF1—conduct disorder	5.17e-05	0.000437	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—WASF1—conduct disorder	5.17e-05	0.000437	CbGpPWpGaD
Lisuride—ADRA2A—brain—conduct disorder	5.17e-05	0.0245	CbGeAlD
Lisuride—ADRA2C—Signaling by GPCR—DRD4—conduct disorder	5.16e-05	0.000436	CbGpPWpGaD
Lisuride—DRD2—GPCR downstream signaling—DRD4—conduct disorder	5.15e-05	0.000435	CbGpPWpGaD
Lisuride—HTR1D—GPCR downstream signaling—HTR2A—conduct disorder	5.13e-05	0.000434	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—DRD4—conduct disorder	5.08e-05	0.000429	CbGpPWpGaD
Lisuride—HTR2A—GPCR downstream signaling—DRD4—conduct disorder	5.07e-05	0.000428	CbGpPWpGaD
Lisuride—HTR1B—GPCR downstream signaling—HTR2A—conduct disorder	5.03e-05	0.000425	CbGpPWpGaD
Lisuride—DRD4—GPCR downstream signaling—HTR2A—conduct disorder	4.95e-05	0.000418	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CGA—conduct disorder	4.94e-05	0.000417	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CGA—conduct disorder	4.86e-05	0.00041	CbGpPWpGaD
Lisuride—HTR2B—GPCR downstream signaling—HTR2A—conduct disorder	4.72e-05	0.000399	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—WASF1—conduct disorder	4.71e-05	0.000398	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—DRD4—conduct disorder	4.68e-05	0.000395	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—WASF1—conduct disorder	4.67e-05	0.000394	CbGpPWpGaD
Lisuride—HTR1D—Signaling by GPCR—HTR2A—conduct disorder	4.66e-05	0.000394	CbGpPWpGaD
Lisuride—ADRA2A—GPCR downstream signaling—DRD4—conduct disorder	4.61e-05	0.00039	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—DRD4—conduct disorder	4.6e-05	0.000389	CbGpPWpGaD
Lisuride—HTR1B—Signaling by GPCR—HTR2A—conduct disorder	4.56e-05	0.000386	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—WASF1—conduct disorder	4.51e-05	0.000381	CbGpPWpGaD
Lisuride—DRD4—Signaling by GPCR—HTR2A—conduct disorder	4.49e-05	0.00038	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—WASF1—conduct disorder	4.48e-05	0.000379	CbGpPWpGaD
Lisuride—DRD1—GPCR downstream signaling—HTR2A—conduct disorder	4.45e-05	0.000376	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CGA—conduct disorder	4.42e-05	0.000373	CbGpPWpGaD
Lisuride—HTR2A—brain—conduct disorder	4.39e-05	0.0208	CbGeAlD
Lisuride—DRD3—GPCR downstream signaling—HTR2A—conduct disorder	4.39e-05	0.000371	CbGpPWpGaD
Lisuride—ADRA1D—GPCR downstream signaling—HTR2A—conduct disorder	4.39e-05	0.000371	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—WASF1—conduct disorder	4.36e-05	0.000368	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—WASF1—conduct disorder	4.29e-05	0.000363	CbGpPWpGaD
Lisuride—HTR2B—Signaling by GPCR—HTR2A—conduct disorder	4.29e-05	0.000362	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—DRD4—conduct disorder	4.22e-05	0.000357	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—DRD4—conduct disorder	4.19e-05	0.000354	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—DRD4—conduct disorder	4.13e-05	0.000349	CbGpPWpGaD
Lisuride—DRD1—Signaling by GPCR—HTR2A—conduct disorder	4.04e-05	0.000342	CbGpPWpGaD
Lisuride—ADRB1—GPCR downstream signaling—HTR2A—conduct disorder	4e-05	0.000338	CbGpPWpGaD
Lisuride—CYP2D6—brain—conduct disorder	4e-05	0.019	CbGeAlD
Lisuride—ADRA1D—Signaling by GPCR—HTR2A—conduct disorder	3.99e-05	0.000337	CbGpPWpGaD
Lisuride—DRD3—Signaling by GPCR—HTR2A—conduct disorder	3.99e-05	0.000337	CbGpPWpGaD
Lisuride—ADRA2B—GPCR downstream signaling—HTR2A—conduct disorder	3.97e-05	0.000335	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—WASF1—conduct disorder	3.96e-05	0.000334	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—WASF1—conduct disorder	3.89e-05	0.000329	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—DRD4—conduct disorder	3.88e-05	0.000328	CbGpPWpGaD
Lisuride—HTR1A—GPCR downstream signaling—HTR2A—conduct disorder	3.83e-05	0.000324	CbGpPWpGaD
Lisuride—HTR2C—GPCR downstream signaling—HTR2A—conduct disorder	3.81e-05	0.000322	CbGpPWpGaD
Lisuride—ADRA2C—GPCR downstream signaling—HTR2A—conduct disorder	3.71e-05	0.000313	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—DRD4—conduct disorder	3.66e-05	0.000309	CbGpPWpGaD
Lisuride—ADRA1B—GPCR downstream signaling—HTR2A—conduct disorder	3.65e-05	0.000308	CbGpPWpGaD
Lisuride—ADRB1—Signaling by GPCR—HTR2A—conduct disorder	3.64e-05	0.000307	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—DRD4—conduct disorder	3.61e-05	0.000305	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—DRD4—conduct disorder	3.61e-05	0.000305	CbGpPWpGaD
Lisuride—ADRA2B—Signaling by GPCR—HTR2A—conduct disorder	3.6e-05	0.000304	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—HTR2A—conduct disorder	3.6e-05	0.000304	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—WASF1—conduct disorder	3.54e-05	0.000299	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—HTR2A—conduct disorder	3.48e-05	0.000294	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—HTR2A—conduct disorder	3.46e-05	0.000292	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—CGA—conduct disorder	3.44e-05	0.000291	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—HTR2A—conduct disorder	3.36e-05	0.000284	CbGpPWpGaD
Lisuride—DRD2—GPCR downstream signaling—HTR2A—conduct disorder	3.36e-05	0.000284	CbGpPWpGaD
Lisuride—ADRA2B—Hemostasis—EP300—conduct disorder	3.33e-05	0.000281	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—HTR2A—conduct disorder	3.31e-05	0.00028	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—DRD4—conduct disorder	3.29e-05	0.000278	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—DRD4—conduct disorder	3.26e-05	0.000276	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—DRD4—conduct disorder	3.15e-05	0.000266	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—DRD4—conduct disorder	3.13e-05	0.000265	CbGpPWpGaD
Lisuride—ADRA2C—Hemostasis—EP300—conduct disorder	3.11e-05	0.000262	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—HTR2A—conduct disorder	3.05e-05	0.000258	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—DRD4—conduct disorder	3.05e-05	0.000257	CbGpPWpGaD
Lisuride—ADRA2A—GPCR downstream signaling—HTR2A—conduct disorder	3.01e-05	0.000254	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—DRD4—conduct disorder	3e-05	0.000253	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—COMT—conduct disorder	2.94e-05	0.000248	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—MAOA—conduct disorder	2.92e-05	0.000246	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—DRD4—conduct disorder	2.76e-05	0.000234	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—HTR2A—conduct disorder	2.75e-05	0.000233	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—HTR2A—conduct disorder	2.73e-05	0.000231	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—DRD4—conduct disorder	2.72e-05	0.00023	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—HTR2A—conduct disorder	2.7e-05	0.000228	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—HTR2A—conduct disorder	2.65e-05	0.000224	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—HTR2A—conduct disorder	2.53e-05	0.000214	CbGpPWpGaD
Lisuride—ADRA2A—Hemostasis—EP300—conduct disorder	2.52e-05	0.000213	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—DRD4—conduct disorder	2.47e-05	0.000209	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—HTR2A—conduct disorder	2.39e-05	0.000202	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—COMT—conduct disorder	2.39e-05	0.000202	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—MAOA—conduct disorder	2.37e-05	0.0002	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—HTR2A—conduct disorder	2.36e-05	0.000199	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—HTR2A—conduct disorder	2.36e-05	0.000199	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—CGA—conduct disorder	2.25e-05	0.00019	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—HTR2A—conduct disorder	2.15e-05	0.000181	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—HTR2A—conduct disorder	2.13e-05	0.00018	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—HTR2A—conduct disorder	2.05e-05	0.000174	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—HTR2A—conduct disorder	2.04e-05	0.000173	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—HTR2A—conduct disorder	1.99e-05	0.000168	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—HTR2A—conduct disorder	1.96e-05	0.000165	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—EP300—conduct disorder	1.9e-05	0.000161	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—HTR2A—conduct disorder	1.8e-05	0.000152	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—HTR2A—conduct disorder	1.61e-05	0.000136	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—COMT—conduct disorder	1.55e-05	0.000131	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—MAOA—conduct disorder	1.54e-05	0.00013	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—EP300—conduct disorder	1.46e-05	0.000123	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—EP300—conduct disorder	1.43e-05	0.000121	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—EP300—conduct disorder	1.41e-05	0.000119	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—EP300—conduct disorder	1.34e-05	0.000113	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—EP300—conduct disorder	1.27e-05	0.000107	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—EP300—conduct disorder	1.26e-05	0.000106	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—EP300—conduct disorder	1.25e-05	0.000106	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—EP300—conduct disorder	1.25e-05	0.000106	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—EP300—conduct disorder	1.14e-05	9.62e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—EP300—conduct disorder	1.13e-05	9.53e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—EP300—conduct disorder	1.09e-05	9.2e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—EP300—conduct disorder	1.08e-05	9.15e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—EP300—conduct disorder	1.05e-05	8.9e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—EP300—conduct disorder	1.04e-05	8.76e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—EP300—conduct disorder	1.02e-05	8.64e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—COMT—conduct disorder	1.02e-05	8.59e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—MAOA—conduct disorder	1.01e-05	8.53e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—EP300—conduct disorder	9.56e-06	8.07e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—EP300—conduct disorder	9.4e-06	7.95e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—EP300—conduct disorder	8.55e-06	7.23e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—EP300—conduct disorder	6.67e-06	5.63e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—EP300—conduct disorder	4.36e-06	3.68e-05	CbGpPWpGaD
